Cure of HCV related liver disease (Q38295834)

1 September 2017

1 reference

title

Cure of HCV related liver disease (English)

1 reference

1 September 2017

Mitchell L Shiffman

1

1 reference

PubMed ID

25529090

1 September 2017

Yves Benhamou

series ordinal

2

1 reference

1 September 2017

1 January 2015

1 reference

1 September 2017

1 reference

1 September 2017

35 Suppl 1

1 reference

1 September 2017

71-77

1 reference

Epidemiology of hepatitis B and C viruses: a global overview

1 September 2017

1 reference

Epidemiology of hepatitis C virus infection

21 January 2018

1 reference

Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis c.

21 January 2018

1 reference

Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression

21 January 2018

1 reference

Rate of natural disease progression in patients with chronic hepatitis C.

21 January 2018

1 reference

Hepatocellular carcinoma: predisposing conditions and precursor lesions

21 January 2018

1 reference

The natural history of compensated cirrhosis due to hepatitis C virus: A 17-year cohort study of 214 patients

21 January 2018

1 reference

Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death.

21 January 2018

1 reference

Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression

21 January 2018

1 reference

The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007.

21 January 2018

1 reference

The global impact of hepatic fibrosis and end-stage liver disease.

21 January 2018

1 reference

When to consider liver transplant during the management of chronic liver disease

21 January 2018

1 reference

Extrahepatic manifestations of infection with hepatitis C virus

21 January 2018

1 reference

Hepatitis C virus, cryoglobulinaemia, and vasculitis: immune complex relations

21 January 2018

1 reference

Cryoglobulinemia vasculitis: an update

21 January 2018

1 reference

Impact of hepatitis C on health related quality of life: a systematic review and quantitative assessment

21 January 2018

1 reference

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

21 January 2018

1 reference

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

21 January 2018

1 reference

Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection

21 January 2018

1 reference

Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3.

21 January 2018

1 reference

Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus

21 January 2018

1 reference

A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin

21 January 2018

1 reference

Long-term clearance of hepatitis C virus following interferon α-2b or peginterferon α-2b, alone or in combination with ribavirin.

21 January 2018

1 reference

HCV direct-acting antiviral agents: the best interferon-free combinations

21 January 2018

1 reference

Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study

21 January 2018

1 reference

Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis

21 January 2018

1 reference

Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection

21 January 2018

1 reference

Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection

21 January 2018

1 reference

Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection

21 January 2018

1 reference

ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV.

21 January 2018

1 reference

ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis

21 January 2018

1 reference

Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin

21 January 2018

1 reference

Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin

21 January 2018

1 reference

Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options

21 January 2018

1 reference

Sofosbuvir and ribavirin in HCV genotypes 2 and 3.

21 January 2018

1 reference

A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. Multicenter Study Group

21 January 2018

1 reference

Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: A 5-year follow-up of 150 patients

21 January 2018

1 reference

Late autoimmune hepatitis after hepatitis C therapy.

21 January 2018

1 reference

Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C.

21 January 2018

1 reference

Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C.

21 January 2018

1 reference

Treatment failure may lead to accelerated fibrosis progression in patients with chronic hepatitis C.

21 January 2018

1 reference

Boceprevir for untreated chronic HCV genotype 1 infection

21 January 2018

1 reference

Telaprevir for previously untreated chronic hepatitis C virus infection

21 January 2018

1 reference

Boceprevir for previously treated chronic HCV genotype 1 infection

21 January 2018

1 reference

Sofosbuvir for previously untreated chronic hepatitis C infection

21 January 2018

1 reference

Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis.

21 January 2018

1 reference

Outcome of sustained virological responders with histologically advanced chronic hepatitis C.

21 January 2018

1 reference

A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C.

21 January 2018

1 reference

Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis.

21 January 2018

1 reference

The risk of long-term morbidity and mortality in patients with chronic hepatitis C: results from an analysis of data from a Department of Veterans Affairs Clinical Registry

21 January 2018

1 reference

Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy

21 January 2018

1 reference

Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis

21 January 2018

1 reference

Cryoglobulinemia is associated with steatosis and fibrosis in chronic hepatitis C.

21 January 2018

1 reference

The impact of obesity and metabolic syndrome on chronic hepatitis C.

21 January 2018

1 reference

Interferon-alpha and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis

21 January 2018

1 reference

Influence of antiviral therapy in hepatitis C virus-associated cryoglobulinemic MPGN.

21 January 2018

1 reference

Peripheral neuropathy in hepatitis-related mixed cryoglobulinemia: electrophysiologic follow-up study

21 January 2018

1 reference

Systematic review: regression of lymphoproliferative disorders after treatment for hepatitis C infection.

21 January 2018

1 reference

Viral elimination reduces incidence of malignant lymphoma in patients with hepatitis C.

21 January 2018

1 reference

Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C.

21 January 2018

1 reference

Antiviral treatment for hepatitis C virus infection is associated with improved renal and cardiovascular outcomes in diabetic patients

21 January 2018

1 reference

Fatigue and health-related quality of life (HRQL) in chronic hepatitis C virus infection

21 January 2018

1 reference

Deterioration of health-related quality of life and fatigue in patients with chronic hepatitis C: Association with demographic factors, inflammatory activity, and degree of fibrosis.

21 January 2018

1 reference

Quality of life considerations for patients with chronic hepatitis C.

21 January 2018

1 reference

Fatigue in patients with chronic hepatitis C.

21 January 2018

1 reference

21 January 2018

1 reference

Patient-reported outcomes in chronic hepatitis C patients with cirrhosis treated with sofosbuvir-containing regimens

21 January 2018

1 reference

Minimal impact of sofosbuvir and ribavirin on health related quality of life in chronic hepatitis C (CH-C).

21 January 2018

1 reference

Slow regression of liver fibrosis presumed by repeated biomarkers after virological cure in patients with chronic hepatitis C

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/LIV.12734

1 reference

1 September 2017

1 reference

PubMed ID

25529090